Product image of Minims Cyclopentolate Hydrochloride Bausch + Lomb Ireland (Cyclopentolate Hydrochloride) supplied by GNH India

Minims Cyclopentolate Hydrochloride Bausch + Lomb Ireland

Active Ingredient:
Cyclopentolate Hydrochloride
Origin:
EU

Minims Cyclopentolate Hydrochloride Bausch + Lomb Ireland (Cyclopentolate Hydrochloride)

Cyclopentolate Hydrochloride, the active ingredient in Minims Cyclopentolate Hydrochloride Bausch + Lomb Ireland, is an anticholinergic (cycloplegic) agent presented as eye drops for ocular use. It induces pupil dilation and temporary paralysis of the ciliary muscle to facilitate eye examinations and procedures.

GNH India supplies Minims Cyclopentolate Hydrochloride Bausch + Lomb Ireland as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Manufacturer / TM Owner

Bausch + Lomb Ireland Limited

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Cyclopentolate Hydrochloride is used in ophthalmic practice to produce cycloplegia and mydriasis for diagnostic and therapeutic procedures.

  • Eye examination: provides mydriasis to allow thorough retinal evaluation.
  • Refractive error assessment: induces cycloplegia to accurately measure refractive errors.
  • Intraocular surgery: facilitates surgical access by dilating the pupil.
  • Anterior segment imaging: improves visualization of anterior chamber structures.

How It Works

  • Cyclopentolate Hydrochloride acts as a competitive antagonist at muscarinic acetylcholine receptors in the iris sphincter and ciliary body. By blocking these receptors, it relaxes the sphincter muscle, leading to pupil dilation (mydriasis), and paralyzes the ciliary muscle, producing cycloplegia that temporarily inhibits accommodation.

Side Effects

Cyclopentolate eye drops may cause ocular and systemic adverse reactions.

Common Side Effects

  • Blurred vision: temporary difficulty focusing after administration.
  • Light sensitivity: increased discomfort in bright environments.
  • Stinging or burning: mild ocular irritation upon instillation.
  • Redness of the eye: conjunctival hyperemia.
  • Increased intraocular pressure: transient rise in pressure.

Serious or Rare Side Effects

  • Acute angle‑closure glaucoma: sudden painful vision loss requiring immediate care.
  • Allergic reaction: swelling, rash, or severe eye irritation.
  • Systemic anticholinergic effects: dry mouth, tachycardia, or confusion (rare).

Precautions & Warnings

When using Cyclopentolate Hydrochloride, consider the following precautions.

  • Contraindication: avoid in patients with known hypersensitivity to cyclopentolate or other anticholinergics.
  • Caution: use carefully in individuals with narrow anterior chamber angles or glaucoma risk.
  • Pregnancy: safety not established; prescribe only if benefit outweighs potential risk.
  • Breastfeeding: unknown excretion; consider risk versus benefit before use.
  • Interaction with other mydriatics: avoid simultaneous use to prevent excessive pupil dilation.
  • Store at room temperature: keep in original container, protect from light and moisture.

Avoid Interactions

Cyclopentolate may interact with other medicines; monitor accordingly.

Major Interactions (Avoid)

  • Other anticholinergic agents: additive systemic anticholinergic effects.
  • Monoamine oxidase inhibitors (MAOIs): potential for exaggerated ocular pressure changes.

Moderate Interactions (Monitor Closely)

  • Topical beta‑blockers: may mask intraocular pressure rise.
  • Systemic antihistamines: can increase anticholinergic burden.
  • Sympathomimetic eye drops (e.g., phenylephrine): may cause excessive mydriasis.

Frequently Asked Questions

Minims Cyclopentolate Hydrochloride is an ophthalmic eye‑drop formulation used to produce temporary pupil dilation (mydriasis) and paralysis of the ciliary muscle (cycloplegia). These effects facilitate comprehensive eye examinations, accurate refractive error measurements, and intraocular surgical procedures.

Cyclopentolate hydrochloride blocks muscarinic acetylcholine receptors in the iris sphincter and ciliary body. This antagonism relaxes the sphincter muscle, causing the pupil to enlarge, and inhibits the ciliary muscle, preventing accommodation. The combined action results in a clear view of intraocular structures.

The specific dose and frequency are determined by the prescribing eye‑care professional based on the intended examination or procedure. The prescriber will decide the number of drops and timing that best suit the patient’s clinical needs.

Safety data for cyclopentolate in pregnancy and lactation are limited. It should only be used when the potential benefit justifies any possible risk to the fetus or infant, and the decision should be made by the treating physician.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Cyclopentolate provides both mydriasis and cycloplegia, whereas agents like tropicamide primarily cause dilation with minimal cycloplegic effect. Compared with phenylephrine, cyclopentolate works via anticholinergic pathways rather than adrenergic stimulation, offering a different safety and duration profile.

Store the eye‑drop bottle at room temperature, preferably below 25 °C, in its original packaging. Protect it from direct light and moisture to maintain stability and potency throughout its shelf life.

The product is applied topically to the conjunctival sac of the eye. Typically, one or more drops are instilled as directed by the eye‑care professional, with care to avoid contamination of the dropper tip.

The most serious adverse events include acute angle‑closure glaucoma, which can cause sudden vision loss, and systemic anticholinergic toxicity manifesting as severe dry mouth, tachycardia, confusion, or urinary retention. Immediate medical attention is required if these occur.

Patients with known hypersensitivity to cyclopentolate or other anticholinergic agents, those with narrow anterior chamber angles at risk for angle‑closure glaucoma, and individuals for whom the prescriber determines the risks outweigh the benefits should avoid using this medication.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Cyclopentolate Hydrochloride

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT